Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 30
PT-141 microdosing: what the label says
Daily sub-label PT-141 schedules sit outside the Vyleesi label and well below the lowest dose ever taken into a published controlled trial.
T-BEAT Japan: design, not results
The T-BEAT paper describes a Japanese tirzepatide and oral semaglutide study, but reports baseline data rather than treatment outcomes.
Tirzepatide and SGLT2 drugs in HFpEF
A 2026 review sets tirzepatide against the SGLT2 inhibitors in obesity-related HFpEF. The mechanisms look complementary. No trial has tested them together.
MASH screening in type 2 diabetes
A new model finds staged, non-invasive MASH screening cost-effective for adults with type 2 diabetes across six countries.
Melanotan 1: why the tan comes out patchy
Melanotan 1 triggers melanin in all skin, not just sun-exposed surfaces, which explains tiger-stripe pigmentation in people with loose or aged skin.
A semaglutide case report on dysautonomia
A 2026 case report described symptom improvement after semaglutide in one patient with dysautonomia. It does not establish a treatment.
Semaglutide and endothelial markers
A post hoc randomized-trial analysis found mixed endothelial marker results after 32 weeks of semaglutide in type 2 diabetes.
TB-500 in 2026 Q2: what changed
Q2 2026 gave TB-500 an FDA compounding review date and one new thymosin beta 4 heart trial, while the injury recovery evidence stayed still.
Tesamorelin in 2026 Q2: what changed
Q2 2026 gave tesamorelin one null cognition pilot and three reviews. Its FDA label, its EU status and its trial pipeline all stayed put.
Does tirzepatide cut carpal tunnel risk?
A 2026 cohort study links tirzepatide to fewer carpal tunnel diagnoses than other weight drugs. That is an association, not a treatment effect.
Tirzepatide: 6-month US persistence data
68% of US adults who started tirzepatide stayed on it at six months. A claims study of 22,512 initiators shows real-world persistence outside the trial setting.
Tirzepatide in 2026 Q2: what changed
Q2 2026 brought tirzepatide maintenance data, an FDA 503B compounding proposal, and warning letters about unapproved and compounded products.